Skip to main content

Advertisement

SpringerLink
Log in

Factors Influencing the Therapeutic Potential of the MSC-derived Secretome

  • Review
  • Published:
Regenerative Engineering and Translational Medicine Aims and scope Submit manuscript

Abstract

Factors and molecules secreted by mesenchymal stem cells (MSCs) can be termed as “secretome.” The MSC-derived secretome includes growth factors, cytokines, chemokines, immunomodulatory molecules, miRNAs, and extracellular vesicles. The composition of the MSC-derived secretome varies and depends on multiple factors to which the MSCs are exposed to. The manipulation of the content of MSC-derived secretomes can be performed by choosing appropriate donors and applying appropriate preconditioning techniques that are used during cell culturing. Therefore, this review focuses on explaining the effect of donor conditions and certain cell culturing-related manipulations on the MSC-derived secretome content. Aging significantly decreases the quality of the collected MSCs; in fact, it does so in a similar manner to donor collection from a patient. MSC expansion under hypoxic conditions and/or in the presence of inflammatory growth factors releases inflammatory and vasculogenic cytokines, thereby promoting the immunomodulatory properties when applied as a part of a potential MSC-derived secretome therapy. By understanding both the importance of the different donor conditions (such as his/her age and health status) and central role that growth factors play during MSC cell culturing, standardizing MSC-derived secretome production for clinical applications could be better achieved. However, the development and clinical applicability of a large-scale MSC-derived secretome production require further research.

Lay Summary

Donor conditions and the application of certain cell culturing related manipulations during in vitro culturing of mesenchymal stem cells (MSCs) affect the MSC-derived secretome.Preconditioning can alter the MSC extracellular cargo, such as the proteins, growth factors, cytokines, miRNAs, and metabolites. The extracellular cargo is currently used in regenerative medicine for clinical applications. Therefore, it is important to understand the efficacy of preconditioning during the culturing process to standardize MSC-derived secretome production.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

The journal articles and original resources used to support the statements included in this article are appropriately and accurately cited within the text and in the article’s reference list.

References

  1. Sagaradze G, Grigorieva O, Nimiritsky P, Basalova N, Kalinina N, Akopyan Z, et al. Conditioned medium from Human mesenchymal stromal cells: towards the clinical translation. Int J Mol Sci. 2019;20:1656.

    Article  CAS  Google Scholar 

  2. Ferreira JR, Teixeira GQ, Santos SG, Barbosa MA, Almeida-Porada G, Gonçalves RM. Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning. Front Immunol. 2018;9:2837.

    Article  CAS  Google Scholar 

  3. da Cruz IBM, Severo AL, Azzolin VF, Garcia LFM, Kuhn A, Lech O. Regenerative potential of the cartilaginous tissue in mesenchymal stem cells: update, limitations, and challenges. Rev Bras Ortop Engl Ed. 2017;52:2–10.

    Article  Google Scholar 

  4. Pk L, Kandoi S, Misra RSVKR, Verma RS. The mesenchymal stem cell secretome: a new paradigm towards cell-free therapeutic mode in regenerative medicine. Cytokine Growth Factor Rev. 2019;46:1–9.

    Article  Google Scholar 

  5. Rezaie J, Heidarzadeh M, Hassanpour M, Amini H, Shokrollahi E, Ahmadi M, et al. The angiogenic paracrine potential of mesenchymal stem cells. Mesenchymal Stem Cells Work Title [Internet]. IntechOpen; 2019. https://www.intechopen.com/online-first/the-angiogenic-paracrine-potential-of-mesenchymal-stem-cells Accessed  12 Jan 2020

  6. Regmi S, Pathak S, Kim JO, Yong CS, Jeong J-H. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives. Eur J Cell Biol. 2019;98:151041.

    Article  CAS  Google Scholar 

  7. Khubutiya MS, Vagabov AV, Temnov AA, Sklifas AN. Paracrine mechanisms of proliferative, anti-apoptotic and anti-inflammatory effects of mesenchymal stromal cells in models of acute organ injury. Cytotherapy. 2014;16:579–85.

    Article  CAS  Google Scholar 

  8. Labrador-Velandia S, Alonso-Alonso ML, Di Lauro S, García-Gutierrez MT, Srivastava GK, Pastor JC, et al. Mesenchymal stem cells provide paracrine neuroprotective resources that delay degeneration of co-cultured organotypic neuroretinal cultures. Exp Eye Res. 2019;185:107671.

    Article  CAS  Google Scholar 

  9. Sung DK, Chang YS, Sung SI, Yoo HS, Ahn SY, Park WS. Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta-defensin-2 via toll-like receptor 4 signalling. Cell Microbiol. 2016;18:424–36.

    Article  CAS  Google Scholar 

  10. Saeedi P, Halabian R, Imani Fooladi AA. A revealing review of mesenchymal stem cells therapy, clinical perspectives and modification strategies. Stem Cell Investig. 2019;6:34–34.

    Article  CAS  Google Scholar 

  11. Zhou Y, Yamamoto Y, Xiao Z, Ochiya T. The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity. J Clin Med. 2019;8:1025.

    Article  CAS  Google Scholar 

  12. Sun DZ, Abelson B, Babbar P, Damaser MS. Harnessing the mesenchymal stem cell secretome for regenerative urology. Nat Rev Urol. 2019;16:363–75.

    Article  Google Scholar 

  13. Martins M, Ribeiro D, Martins A, Reis RL, Neves NM. Extracellular vesicles derived from osteogenically induced human bone marrow mesenchymal stem cells can modulate lineage commitment. Stem Cell Rep. 2016;6:284–91.

    Article  CAS  Google Scholar 

  14. Haque N, Rahman MT, Abu Kasim NH, Alabsi AM. Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy. Sci World J. 2013;2013:1–12.

    Article  Google Scholar 

  15. Eleuteri S, Fierabracci A. Insights into the secretome of mesenchymal stem cells and its potential applications. Int J Mol Sci. 2019;20:4597.

    Article  CAS  Google Scholar 

  16. Kusuma GD, Carthew J, Lim R, Frith JE. Effect of the microenvironment on mesenchymal stem cell paracrine signaling: opportunities to engineer the therapeutic effect. Stem Cells Dev. 2017;26:617–31.

    Article  CAS  Google Scholar 

  17. Assoni A, Coatti G, Valadares MC, Beccari M, Gomes J, Pelatti M, et al. Different donors mesenchymal stromal cells secretomes reveal heterogeneous profile of relevance for therapeutic use. Stem Cells Dev. 2017;26:206–14.

    Article  CAS  Google Scholar 

  18. Pires AO, Mendes-Pinheiro B, Teixeira FG, Anjo SI, Ribeiro-Samy S, Gomes ED, et al. Unveiling the differences of secretome of human bone marrow mesenchymal stem cells, adipose tissue-derived stem cells, and human umbilical cord perivascular cells: a proteomic analysis. Stem Cells Dev. 2016;25:1073–83.

    Article  CAS  Google Scholar 

  19. Tachida Y, Sakurai H, Okutsu J. Proteomic comparison of the secreted factors of mesenchymal stem cells from bone marrow, adipose tissue and dental pulp. J Proteomics Bioinform [Internet]. 2015;8. Available from: https://www.omicsonline.org/open-access/proteomic-comparison-of-the-secreted-factors-of-mesenchymal-stemcells-from-bone-marrow-adipose-tissue-and-dental-pulp-jpb-1000379.php?aid=64718. Accessed 13 Mar 2021.

  20. Shin S, Lee J, Kwon Y, Park K-S, Jeong J-H, Choi S-J, et al. Comparative proteomic analysis of the mesenchymal stem cells secretome from adipose, bone marrow, placenta and Wharton’s jelly. Int J Mol Sci. 2021;22:845.

    Article  CAS  Google Scholar 

  21. Kyurkchiev D. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells. 2014;6:552.

    Article  Google Scholar 

  22. Leuning DG, Beijer NRM, du Fossé NA, Vermeulen S, Lievers E, van Kooten C, et al. The cytokine secretion profile of mesenchymal stromal cells is determined by surface structure of the microenvironment. Sci Rep. 2018;8:7716.

    Article  Google Scholar 

  23. Meiliana A, Dewi NM, Wijaya A. Mesenchymal stem cell secretome: cell-free therapeutic strategy in regenerative medicine. Indones Biomed J [Internet]. 2019;11. Available from: https://inabj.org/index.php/ibj/article/view/839. Accessed 05 Jan 2020.

  24. Melief SM, Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. STEM CELLS Transl Med. 2013;2:455–63.

    Article  Google Scholar 

  25. Pokrovskaya LA, Zubareva EV, Nadezhdin SV, Lysenko AS, Litovkina TL. Biological activity of mesenchymal stem cells secretome as a basis for cell-free therapeutic approach. Res Results Pharmacol. 2020;6:57–68.

    Article  CAS  Google Scholar 

  26. Phelps J, Sanati-Nezhad A, Ungrin M, Duncan NA, Sen A. Bioprocessing of mesenchymal stem cells and their derivatives: toward cell-free therapeutics. Stem Cells Int. 2018;2018:1–23.

    Article  Google Scholar 

  27. Billing AM, Ben Hamidane H, Dib SS, Cotton RJ, Bhagwat AM, Kumar P, et al. Comprehensive transcriptomic and proteomic characterization of human mesenchymal stem cells reveals source specific cellular markers. Sci Rep. 2016;6:21507.

    Article  CAS  Google Scholar 

  28. Schimke MM, Marozin S, Lepperdinger G. Patient-specific age: the other side of the coin in advanced mesenchymal stem cell therapy. Front Physiol [Internet]. 2015 [cited 2020 Apr 29];6. Available from: http://journal.frontiersin.org/Article/https://doi.org/10.3389/fphys.2015.00362/abstract

  29. Efimenko A, Dzhoyashvili N, Kalinina N, Kochegura T, Akchurin R, Tkachuk V, et al. Adipose-derived mesenchymal stromal cells from aged patients with coronary artery disease keep mesenchymal stromal cell properties but exhibit characteristics of aging and have impaired angiogenic potential. STEM CELLS Transl Med. 2014;3:32–41.

    Article  CAS  Google Scholar 

  30. Bermudez MA, Sendon-Lago J, Seoane S, Eiro N, Gonzalez F, Saa J, et al. Anti-inflammatory effect of conditioned medium from human uterine cervical stem cells in uveitis. Exp Eye Res. 2016;149:84–92.

    Article  CAS  Google Scholar 

  31. Siegel G, Kluba T, Hermanutz-Klein U, Bieback K, Northoff H, Schäfer R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013;11:146.

    Article  CAS  Google Scholar 

  32. Sammour I, Somashekar S, Huang J, Batlahally S, Breton M, Valasaki K, et al. The effect of gender on mesenchymal stem cell (MSC) efficacy in neonatal hyperoxia-induced lung injury. Kirchmair R, editor. PLOS ONE. 2016;11:e0164269.

    Article  Google Scholar 

  33. Gray A, Schloss RS, Yarmush M. Donor variability among anti-inflammatory pre-activated mesenchymal stromal cells. Technology. 2016;04:201–15.

    Article  Google Scholar 

  34. Lee RH, Yu JM, Foskett AM, Peltier G, Reneau JC, Bazhanov N, et al. TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc Natl Acad Sci. 2014;111:16766–71.

    Article  CAS  Google Scholar 

  35. Meng Y, Eirin A, Zhu X-Y, Tang H, Chanana P, Lerman A, et al. Obesity-induced mitochondrial dysfunction in porcine adipose tissue-derived mesenchymal stem cells. J Cell Physiol. 2018;233:5926–36.

    Article  CAS  Google Scholar 

  36. Pérez LM, de Lucas B, Lunyak VV, Gálvez BG. Adipose stem cells from obese patients show specific differences in the metabolic regulators vitamin D and Gas5. Mol Genet Metab Rep. 2017;12:51–6.

    Article  Google Scholar 

  37. Pérez LM, Bernal A, de Lucas B, San Martin N, Mastrangelo A, García A, et al. Altered metabolic and stemness capacity of adipose tissue-derived stem cells from obese mouse and human. Engler AJ, editor. PLOS ONE. 2015;10:e0123397.

    Article  Google Scholar 

  38. Silva KR, Liechocki S, Carneiro JR, Claudio-da-Silva C, Maya-Monteiro CM, Borojevic R, et al. Stromal-vascular fraction content and adipose stem cell behavior are altered in morbid obese and post bariatric surgery ex-obese women. Stem Cell Res Ther. 2015;6:72.

    Article  Google Scholar 

  39. Li X, Ma T, Sun J, Shen M, Xue X, Chen Y, et al. Harnessing the secretome of adipose-derived stem cells in the treatment of ischemic heart diseases. Stem Cell Res Ther. 2019;10:196.

    Article  Google Scholar 

  40. Yuan X, Logan TM, Ma T. Metabolism in human mesenchymal stromal cells: a missing link between hmsc biomanufacturing and therapy? Front Immunol. 2019;10:977.

    Article  CAS  Google Scholar 

  41. Sagaradze GD, Nimiritsky PP, Akopyan ZA, Makarevich PI, Efimenko AYu. “Cell-free therapeutics” from Components secreted by mesenchymal stromal cells as a novel class of biopharmaceuticals. In: Yeh M-K, Chen Y-C, editors. Biopharmaceuticals [Internet]. InTech; 2018. Available from:  http://www.intechopen.com/books/biopharmaceuticals/-cell-free-therapeutics-from-components-secreted-by-mesenchymal-stromal-cells-as-a-novel-class-of-bi. Accessed 21 Apr 2020

  42. Oikonomopoulos A, van Deen WK, Manansala A-R, Lacey PN, Tomakili TA, Ziman A, et al. Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media. Sci Rep. 2015;5:16570.

    Article  Google Scholar 

  43. Miwa H, Hashimoto Y, Tensho K, Wakitani S, Takagi M. Xeno-free proliferation of human bone marrow mesenchymal stem cells. Cytotechnology. 2012;64:301–8.

    Article  CAS  Google Scholar 

  44. Al-Ani A, Toms D, Kondro D, Thundathil J, Yu Y, Ungrin M. Oxygenation in cell culture: critical parameters for reproducibility are routinely not reported. Ivanovic Z, editor. PLOS ONE. 2018;13:e0204269.

    Article  Google Scholar 

  45. Baker N, Boyette LB, Tuan RS. Characterization of bone marrow-derived mesenchymal stem cells in aging. Bone. 2015;70:37–47.

    Article  CAS  Google Scholar 

  46. Lee J, Yoon Y, Lee S. Hypoxic preconditioning promotes the bioactivities of mesenchymal stem cells via the HIF-1α-GRP78-Akt axis. Int J Mol Sci. 2017;18:1320.

    Article  Google Scholar 

  47. Mathew SA, Chandravanshi B, Bhonde R. Hypoxia primed placental mesenchymal stem cells for wound healing. Life Sci. 2017;182:85–92.

    Article  CAS  Google Scholar 

  48. Serena C, Keiran N, Ceperuelo-Mallafre V, Ejarque M, Fradera R, Roche K, et al. Obesity and type 2 diabetes alters the immune properties of human adipose derived stem cells: obesity changes the immune properties of stem cells. STEM CELLS. 2016;34:2559–73.

    Article  CAS  Google Scholar 

  49. Volkmer E, Kallukalam BC, Maertz J, Otto S, Drosse I, Polzer H, et al. Hypoxic preconditioning of human mesenchymal stem cells overcomes hypoxia-induced inhibition of osteogenic differentiation. Tissue Eng Part A. 2010;16:153–64.

    Article  CAS  Google Scholar 

  50. Bartaula-Brevik S. Secretome of mesenchymal stem cells grown in hypoxia accelerates wound healing and vessel formation in vitro. Int J Stem Cell Res Ther [Internet]. 2017;4. Available from:  https://clinmedjournals.org/articles/ijscrt/international-journal-of-stem-cell-research-and-therapy-ijscrt-4-045.php?jid=ijscrt. Accessed 26 Jan 2020.

  51. Chen Y-C, Chang Y-W, Tan KP, Shen Y-S, Wang Y-H, Chang C-H. Can mesenchymal stem cells and their conditioned medium assist inflammatory chondrocytes recovery? Vinci MC, editor PLOS ONE. 2018;13:e0205563.

    Article  Google Scholar 

  52. Dostert G, Mesure B, Menu P, Velot É. How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication? Front Cell Dev Biol [Internet]. 2017 [cited 2020 Jan 26];5. Available from: http://journal.frontiersin.org/article/https://doi.org/10.3389/fcell.2017.00006/full

  53. Ti D, Hao H, Tong C, Liu J, Dong L, Zheng J, et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J Transl Med. 2015;13:308.

    Article  Google Scholar 

  54. Lee SC, Jeong HJ, Lee SK, Kim S-J. Lipopolysaccharide preconditioning of adipose-derived stem cells improves liver-regenerating activity of the secretome. Stem Cell Res Ther. 2015;6:75.

    Article  Google Scholar 

  55. Bai Y, Han Y, Yan X, Ren J, Zeng Q, Li X, et al. Adipose mesenchymal stem cell-derived exosomes stimulated by hydrogen peroxide enhanced skin flap recovery in ischemia-reperfusion injury. Biochem Biophys Res Commun. 2018;500:310–7.

    Article  CAS  Google Scholar 

  56. Liu X, Duan B, Cheng Z, Jia X, Mao L, Fu H, et al. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein Cell. 2011;2:845–54.

    Article  CAS  Google Scholar 

  57. Cunningham CJ, Redondo-Castro E, Allan SM. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. J Cereb Blood Flow Metab. 2018;38:1276–92.

    Article  Google Scholar 

  58. Weiss ARR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol. 2019;10:1191.

    Article  CAS  Google Scholar 

  59. Le Blanc K, Davies LC. Mesenchymal stromal cells and the innate immune response. Immunol Lett. 2015;168:140–6.

    Article  Google Scholar 

  60. Kastner N, Mester-Tonczar J, Winkler J, Traxler D, Spannbauer A, Rüger BM, et al. Comparative effect of MSC secretome to MSC co-culture on cardiomyocyte gene expression under hypoxic conditions in vitro. Front Bioeng Biotechnol. 2020;8:502213.

    Article  Google Scholar 

  61. Diaz-Rodriguez P, Erndt-Marino J, Chen H, Diaz-Quiroz JF, Samavedi S, Hahn MS. A bioengineered in vitro osteoarthritis model with tunable inflammatory environments indicates context-dependent therapeutic potential of human mesenchymal stem cells. Regen Eng Transl Med. 2019;5:297–307.

    Article  CAS  Google Scholar 

  62. Potapova IA, Gaudette GR, Brink PR, Robinson RB, Rosen MR, Cohen IS, et al. Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells. 2007;25:1761–8.

    Article  CAS  Google Scholar 

  63. Pankajakshan D, Agrawal DK. Mesenchymal stem cell paracrine factors in vascular repair and regeneration. J Biomed Technol Res [Internet]. 2014;1. Available from: http://www.elynsgroup.com/journal/j-biomed-tech-res/article/mesenchymal-stem-cell-paracrine-factors-in-vascular-repair-and-regeneration. Accessed 12 Jan 2020.

  64. Sart S, Tsai A-C, Li Y, Ma T. Three-dimensional aggregates of mesenchymal stem cells: cellular mechanisms, biological properties, and applications. Tissue Eng Part B Rev. 2014;20:365–80.

    Article  Google Scholar 

  65. Qazi TH, Mooney DJ, Duda GN, Geissler S. Biomaterials that promote cell-cell interactions enhance the paracrine function of MSCs. Biomaterials. 2017;140:103–14.

    Article  CAS  Google Scholar 

  66. Cha JM, Shin EK, Sung JH, Moon GJ, Kim EH, Cho YH, et al. Efficient scalable production of therapeutic microvesicles derived from human mesenchymal stem cells. Sci Rep. 2018;8:1171.

    Article  Google Scholar 

  67. Tao S-C, Guo S-C, Li M, Ke Q-F, Guo Y-P, Zhang C-Q. Chitosan Wound dressings incorporating exosomes derived from microRNA-126-overexpressing synovium mesenchymal stem cells provide sustained release of exosomes and heal full-thickness skin defects in a diabetic rat model: sustained-release SMSC-126-exos in wound healing. STEM CELLS Transl Med. 2017;6:736–47.

    Article  CAS  Google Scholar 

  68. Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18:1852.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Doctoral Program in Pharmacy, Faculty of Pharmacy, University of Padjajaran, Jatinangor, Jawa Barat, Indonesia

    Angliana Chouw

  2. Prodia StemCell Indonesia, Jalan Kramat 7 No 11, Jakarta Pusat, Indonesia

    Angliana Chouw, Geofanny Facicilia & Cynthia Retna Sartika

  3. Stem Cell Working Group, Faculty of Medicine, University of Padjajaran, Bandung, Indonesia

    Ahmad Faried

  4. Biological Pharmacy Department, Faculty of Pharmacy, University of Padjajaran, Jawa Barat, Jatinangor, Indonesia

    Tiana Milanda

Authors
  1. Angliana Chouw
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geofanny Facicilia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cynthia Retna Sartika
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmad Faried
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tiana Milanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CRS conceived the original idea. AC and GF authored the manuscript. AF and TM reviewed the manuscript.

Corresponding author

Correspondence to Angliana Chouw.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chouw, A., Facicilia, G., Sartika, C.R. et al. Factors Influencing the Therapeutic Potential of the MSC-derived Secretome. Regen. Eng. Transl. Med. 8, 384–393 (2022). https://doi.org/10.1007/s40883-021-00242-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40883-021-00242-x

Keywords

Search

Navigation